From 1 November 2021, these antibody tests will allow a doctor to make a more accurate diagnosis and start treating the patient with the correct medicines earlier. This testing is currently claimed under generic MBS item numbers 71119 or 71165, which are non-specific single antibody tests.

Specialists who manage patients with suspected NMOSD and MARD will be able to request a test to determine if a patient has NMOSD or MARD.

This service will lead to more rapid diagnosis and better targeted treatment, to improve patient outcomes.

PDF Version Factsheet for Neuromyelitis OpticaTesting (PDF 204 KB)

Word Version Factsheet for Neuromyelitis OpticaTesting (Word 90 KB)